The FDA is seeking feedback on a list of patient preference areas that it put together to help them take into account patients’ views as they make regulatory decisions about medical devices. Included on this list of patient preference areas is “Ear, Nose, and Throat: Treatments for moderate to severe hearing loss (implanted hearing devices vs. other treatment options).”
The FDA is seeking information or qualitative or quantitative assessments of whether patients prefer certain alternatives, outcomes or choices over others in terms of their health.
The FDA wants to understand how patients view the risks and benefits of a technology or treatment differently from how the risks and benefits are viewed by health-care professionals and caregivers and whether differences in patient perspectives are not well understood due to a variety of factors.
Check out their request for comments on the Federal Register.
Related Posts
Supplemental Benefits In Medicare Advantage (Hearing, Vision, Dental) Under Discussion
On November 4, the Medicare Payment Advisory Commission (MedPAC) discussed how to standardize a set of three or four benefits—potentially hearing, vision and dental services—in Medicare Advantage (MA) for a future recommendation to Congress after MedPAC staff found that people have a more challenging time comparing plans when they have a variety of options. MedPAC…
Academy Provides Recommendations to Congress on Reforming the Medicare Physician Payment System
The Academy submitted comments in response to a congressional Request for Information (RFI) seeking suggestions on how to stabilize the Medicare physician payment system, including reforming the current payment structure so it supports a system that provides greater value to patients and to clinicians. The Academy provided specific recommendations on the Medicare Physician Payment System…
Have You Heard?
An Update for Academy Members from the Academy’s Executive Director
By Patrick Gallagher, MBA, Executive Director Over-the-counter (OTC) hearing aids (HAs) became officially available on Monday, October 17, 2022, and their introduction has been met with much fanfare in the media. Within the Academy community, the reaction has been more measured. The Academy has recognized that OTC HAs may be a way for adults to…